未登录 分享 收藏
分享 收藏
PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening Lee, Jangsoon; Liu, Huey; Pearson, Troy; Iwase, Toshiaki; Fuson, Jon; Lalani, Alshad S.; Eli, Lisa D.; Diala, Irmina; Tripathy, Debu; Lim, Bora; Ueno, Naoto T. 分享 收藏
Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models Veeraraghavan, Jamunarani; Gutierrez, Carolina; Sethunath, Vidyalakshmi; Mehravaran, Sepideh; Giuliano, Mario; Shea, Martin J.; Mitchell, Tamika; Wang, Tao; Nanda, Sarmistha; Pereira, Resel; Davis, Robert; Goutsouliak, Kristina; Qin, Lanfang; De Angelis, Carmine; Diala, Irmina; Lalani, Alshad S.; Nagi, Chandandeep; Hilsenbeck, Susan G.; Rimawi, Mothaffar F.; Osborne, C. Kent; Schiff, Rachel 分享 收藏
Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors Conlon, Neil T.; Kooijman, Jeffrey J.; van Gerwen, Suzanne J. C.; Mulder, Winfried R.; Zaman, Guido J. R.; Diala, Irmina; Eli, Lisa D.; Lalani, Alshad S.; Crown, John; Collins, Denis M. 分享 收藏
分享 收藏
分享 收藏
HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers Li, Bob T.; Michelini, Flavia; Misale, Sandra; Cocco, Emiliano; Baldino, Laura; Cai, Yanyan; Shifman, Sophie; Tu, Hai-Yan; Myers, Mackenzie L.; Xu, Chongrui; Mattar, Marissa; Khodos, Inna; Little, Megan; Qeriqi, Besnik; Weitsman, Gregory; Wilhem, Clare J.; Lalani, Alshad S.; Diala, Irmina; Freedman, Rachel A.; Lin, Nancy U.; Solit, David B.; Berger, Michael F.; Barber, Paul R.; Ng, Tony; Offin, Michael; Isbell, James M.; Jones, David R.; Yu, Helena A.; Thyparambil, Sheeno; Liao, Wei-Li; Bhalkikar, Anuja; Cecchi, Fabiola; Hyman, David M.; Lewis, Jason S.; Buonocore, Darren J.; Ho, Alan L.; Makker, Vicky; Reis-Filho, Jorge S.; Razavi, Pedram; Arcila, Maria E.; Kris, Mark G.; Poirier, John T.; Shen, Ronglai; Tsurutani, Junji; Ulaner, Gary A.; de Stanchina, Elisa; Rosen, Neal; Rudin, Charles M.; Scaltriti, Maurizio 分享 收藏
Neratinib plus capecitabine vs lapatinib plus capecitabine in HER2+metastatic breast cancer previously treated with ≥2 HER2-directed regimens: Exploratory biomarker analyses from phase III NALA trial Saura, C.; Vivancos, A.; Matito, J.; Wildiers, H.; Brufsky, A. M.; Oliveira, M.; Waters, S.; Hurvitz, S. A.; Moy, B.; Kim, S-B.; Gradishar, W. J.; Queiroz, G. S.; Cronemberger, E.; Bebchuk, J.; Keyvanjah, K.; Lalani, A. S.; Eli, L. D.; Delaloge, S. 分享 收藏
Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, breast cancer progression, and HER2 inhibitor sensitivity Hanker, Ariella B.; Jayanthan, Harikrishna Sekar; Ye, Dan; Lin, Chang-Ching; Akamatsu, Hiroaki; Sheehan, Jonathan H.; Koch, James P.; Sudhan, Dhivya R.; Brewer, Monica Red; Servetto, Alberto; He, Jie; Miller, Vincent A.; Lalani, Alshad S.; Meiler, Jens; Arteaga, Carlos L. 分享 收藏
Neratinib plus trastuzumab plus fulvestrant for HER2-mutant, hormone receptor-positive, metastatic breast cancer: Updated results from the phase 2 SUMMIT 'basket' trial Wildiers, Hans; Boni, Valentina; Saura, Cristina; Oliveira, Mafalda; Jhaveri, Komal; Won, Helen; Bidard, Francois-Clement; Brufsky, Adam M.; Burkard, Mark E.; Cervantes, Andres; Fernandez-Martos, Carlos; Haley, Barbara; Loi, Sherene; Spanggaard, Iben; Panni, Stefano; Lu, Janice; Dujka, Melanie E.; Xu, Feng; Macia, Sonia; Eli, Lisa D.; Lalani, Alshad S.; Piha-Paul, Sarina; Meric-Bernstam, Funda; Solit, David B.; Hyman, David M. 分享 收藏
Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer Smyth, Lillian M.; Piha-Paul, Sarina A.; Won, Helen H.; Schram, Alison M.; Saura, Cristina; Loi, Sherene; Lu, Janice; Shapiro, Geoffrey I.; Juric, Dejan; Mayer, Ingrid A.; Arteaga, Carlos L.; de la Fuente, Macarena I.; Brufksy, Adam M.; Spanggaard, Iben; Mau-Sorensen, Morten; Arnedos, Monica; Moreno, Victor; Boni, Valentina; Sohn, Joohyuk; Schwartzberg, Lee S.; Gonzalez-Farre, Xavier; Cervantes, Andres; Bidard, Francois-Clement; Gorelick, Alexander N.; Lanman, Richard B.; Nagy, Rebecca J.; Ulaner, Gary A.; Chandarlapaty, Sarat; Jhaveri, Komal; Gavrila, Elena I.; Zimel, Catherine; Selcuklu, S. Duygu; Melcer, Myra; Samoila, Aliaksandra; Cai, Yanyan; Scaltriti, Maurizio; Mann, Grace; Xu, Feng; Eli, Lisa D.; Dujka, Melanie; Lalani, Alshad S.; Bryce, Richard; Baselga, Jose; Taylor, Barry S.; Solit, David B.; Meric-Bernstam, Funda; Hyman, David M. 分享 收藏
分享 收藏
Combinatorial therapies of neratinib for HER2-amplified cancer Zhao, Ming; Scott, Stephen; Evans, Kurt; Yuca, Erkan; Saridogan, Turcin; Demirhan, Mehmet E.; Kirby, Bryce P.; Kopetz, Scott; Diala, Irmina; Lalani, Alshad S.; Piha-Paul, Sarina A.; Meric-Bernstam, Funda 分享 收藏
Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2+ve breast cancer metastasis 新辅助neratinib在自发性HER2 ve乳腺癌转移的新同基因模型中促进铁死亡并抑制脑转移 Nagpal, Aadya; Redvers, Richard P.; Ling, Xiawei; Ayton, Scott; Fuentes, Miriam; Tavancheh, Elnaz; Diala, Irmina; Lalani, Alshad; Loi, Sherene; David, Steven; Anderson, Robin L.; Smith, Yvonne; Merino, Delphine; Denoyer, Delphine; Pouliot, Normand 分享 收藏
The therapeutic superiority of neratinib in combination with trastuzumab compared to pertuzumab plus trastuzumab in HER2-positive in vivo breast cancer models Veeraraghavan, Jamunarani; Sethunath, Vidyalakshmi; Shea, Martin J.; Mitchell, Tamika; Pereira, Resel; Qin, Lanfang; Nanda, Sarmistha; De Angelis, Carmine; Goutsouliak, Kristina; Diala, Irmina; Lalani, Alshad S.; Mehravaran, Sepideh; Hilsenbeck, Susan G.; Nagi, Chandandeep; Gutierrez, Carolina; Rimawi, Mothaffar F.; Osborne, C. Kent; Schiff, Rachel 分享 收藏
Patient-derived organoids and xenografts identify neratinib plus HER2 antibody drug conjugate as a synergistic drug combination for HER2 mutated, nonamplified metastatic breast cancer Li, Shunqiang; Maureen, Highkin; Primeau, Tina M.; Pratt, Stephanie L.; Diala, Irmina; Cutler, Richard E.; Mann, Grace; Lalani, Alshad S.; Ma, Cynthia X.; Bose, Ron 分享 收藏
KRAS-mutant (mt) colorectal cancer (CRC) organoid models generated from patient-derived xenografts (PDX) show response to combination of trametinib (Tm), neratinib (N), and trastuzumab (Tz) Pal, Rekha; Srinivasan, Ashok; Lucas, Peter C.; Allegra, Carmen J.; Davies, Angela M.; Lalani, Alshad S.; Jacobs, Samuel A.; Pogue-Geile, Katherine L. 分享 收藏
Paired tumor and cfDNA in patients with HER2-mutant solid tumors treated with neratinib reveals convergence of multiple on-target resistance mechanisms: Results from the SUMMIT Basket Trial Won, Helen H.; Selcuklu, S. Duygu; Piha-Paul, Sarina A.; Saura, Cristina; Rodon, Jordi; Mayer, Ingrid A.; Loi, Sherene; Shapiro, Geoffrey I.; Lu, Janice; Brufsky, Adam; Zimel, Catherine; Melcer, Myra; Scaltriti, Maurizio; Eli, Lisa D.; Cutler, Richard E., Jr.; Lalani, Alshad S.; Bryce, Richard P.; Arteaga, Carlos; Meric-Bernstam, Funda; Berger, Michael F.; Solit, David B.; Schram, Alison; Hyman, David M. 分享 收藏
Hyperactivation of mTORC1 drives acquired resistance to the pan -HER tyrosine kinase inhibitor neratinib in HER2-mutant cancers Sudhan, Dhivya R.; Guerrero-Zotano, Angel; Won, Helen; Ericsson, Paula Gonzales; Liu, Qi; Dugger, Teresa; Koch, James; Schram, Alison; Servetto, Alberto; Cutler, Richard; Lalani, Alshad; Bryce, Richard; Auerbach, Alan; Hanker, Ariella; Arteaga, Carlos L. 分享 收藏
.png){kind=icon}
未登录.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
